

# A Metaanalysis of Severe Upper Gastrointestinal Complications of Nonsteroidal Antiinflammatory Drugs

JOSHUA J. OFMAN, CATHERINE H. MACLEAN, WALTER L. STRAUS, SALLY C. MORTON, MARC L. BERGER, ELIZABETH A. ROTH, and PAUL SHEKELLE

**ABSTRACT.** *Objective.* Prior metaanalyses of the risk of upper gastrointestinal (GI) complications associated with nonsteroidal antiinflammatory drugs (NSAID) have focused on the published English language epidemiologic literature and/or only a portion of the relevant evidence, restrictions that are now known to be associated with bias in metaanalysis. We synthesized the published and unpublished evidence to determine the least biased estimates of the risks of perforations, ulcers, and bleeds (PUB) associated with NSAID use from all study designs and all languages.

*Methods.* Data sources: Using MEDLINE, EMBASE, HEALTHSTAR, and BIOSIS, we searched for English and non-English language studies of NSAID from 1966–1998 reporting primary data on GI complications. We obtained unpublished data from the US Food and Drug Administration (FDA) new drug application (NDA) reviews. NDA were hand searched to identify unpublished studies with inclusion criteria identical to those used for published reports. Study selection: Studies had to assess the use of oral NSAID for more than 4 days duration in subjects > 18 years of age and report on the clinically relevant upper GI outcomes of PUB.

*Results.* Two reviewers evaluated 4881 published titles and identified 13 NSAID versus placebo randomized clinical trials and 3 previously unpublished FDA placebo controlled randomized controlled trials, 9 cohort studies, and 23 case control studies sufficiently clinically homogeneous to pool. Two reviewers extracted data about study characteristics and study quality. Data synthesis: The majority of clinical trials were of good quality, but observational studies had methodologic limitations. The pooled odds ratio (OR) from 16 NSAID versus placebo clinical trials, comprising 4431 patients, was 5.36 (95% CI: 1.79, 16.1). The pooled relative risk of PUB from 9 cohort studies comprising over 750,000 person-years of exposure was 2.7 (95% CI: 2.1, 3.5). The pooled OR of PUB from 23 case control studies using age and sex matching, representing 25,732 patients, was 3.0 (95% CI: 2.5, 3.7). Data were insufficient to justify subgroup analyses stratified by age, comorbid conditions, drug, or dose.

*Conclusion.* These data support an association between the use of NSAID and serious upper GI complications, including estimates from different study designs. Prior pooled estimates about the effect of patient and drug variables on increased risk must be viewed with caution. (J Rheumatol 2002;29:804–12)

## Key Indexing Terms:

NONSTEROIDAL ANTIINFLAMMATORY DRUGS  
UPPER GASTROINTESTINAL HEMORRHAGE

PEPTIC ULCER DISEASE  
COMPLICATIONS

From the Southern California Evidence-Based Practice Center, which includes: the Departments of Medicine and Health Services Research, Division of Gastroenterology, Cedars-Sinai Health System, and Zynx Health Inc.; Department of Medicine, Division of Rheumatology, UCLA School of Medicine, Los Angeles; RAND, Santa Monica; Department of Medicine, West-Los Angeles VAMC, Los Angeles, CA; and Merck and Co. Inc., West Point, PA, USA.

Supported by a contract from Merck & Co. Dr. Shekelle is a Senior Research Associate of the Veterans Affairs Health Services Research and Development Service.

J.J. Ofman, MD, MSHS, Departments of Medicine and Health Services Research, Division of Gastroenterology, Cedars-Sinai Health System, and Zynx Health Inc.; C.H. MacLean, MD, Department of Medicine, Division of Rheumatology, UCLA School of Medicine, Los Angeles, and RAND; W.L. Straus, MD, MPH, Merck and Co. Inc.; S.C. Morton, PhD; M.L. Berger, MD; E.A. Roth, MA, RAND; P. Shekelle, MD, PhD, RAND, and Department of Medicine, West-Los Angeles VAMC.

Address reprint requests to Dr. J. Ofman, Cedars Sinai, Zynx Health, 9100 Wilshire Blvd., Ste. 655, Beverly Hills, CA 90212.

Submitted March 2, 2001; revision accepted January 2, 2002.

Nonsteroidal antiinflammatory drugs (NSAID) are used on a regular basis by about 20 million persons in the United States<sup>1</sup> and roughly 70 million prescriptions are written annually<sup>2</sup>. The use of NSAID increases with age, and the point prevalence of prescription NSAID use is 10–15% in persons older than 65.3 years<sup>3,4</sup>. The most common adverse effects of NSAID are gastrointestinal (GI) complications, which range from mild dyspepsia to life-threatening ulcer complications such as perforation, ulcers, and bleeds (PUB)<sup>5</sup>, which may be the result of inhibition of mucosal prostaglandin production<sup>6</sup>. The direct costs attributable to the GI complications of NSAID have been estimated to approach 1.6 billion dollars annually<sup>5</sup>.

Several systematic reviews have attempted to provide estimates of the risks of upper GI complications of NSAID<sup>7–13</sup>. The pooled relative risk of PUB has been estimated as

2.7<sup>11</sup>, 3.8<sup>8</sup>, 4.0<sup>9</sup>, and between 3.0 and 5.0 for individual drugs<sup>10</sup>. While each study has strengths, these analyses have limitations including restricting the analysis to observational studies, analyzing only data available in the English language, and relying solely on the published literature. Each of these methodologic limitations has been empirically demonstrated to be associated with bias in metaanalyses<sup>14-16</sup>. Our objective was to produce the least biased metaanalysis of the relationship between NSAID use and severe GI complications by assessing the effects of NSAID on PUB, including available published and unpublished data without language restrictions, and examining all study designs.

## MATERIALS AND METHODS

We performed a systematic review of the medical literature for studies reporting primary data regarding the GI complications of the oral use of NSAID. We searched the MEDLINE, BIOSIS, EMBASE, and HEALTHSTAR computerized bibliographic databases from 1966 to 1998 (Table 1). Bibliographies from previous systematic reviews and personal files were also reviewed, and articles included in previous systematic reviews were screened. We searched for unpublished data by requesting data from the US Food and Drug Administration (FDA) under the Freedom of Information Act. The search was not restricted by study design or language. All stages of the review were performed independently by 2 physician reviewers trained in health services research and the principles of critical appraisal. Disagreement between reviewers was resolved by consensus.

The search strategy identified 4881 published titles (see Figure 1 for outcome of literature search). Titles were rejected only when it was clear that the article was an animal study or that it did not pertain to oral NSAID. Abstracts were obtained for all titles that passed title screening, and 2177 abstracts were reviewed. Abstracts were rejected if they met any of the following explicit criteria: failed title inclusion criteria; the article was a review, editorial, letter, clinical practice guideline, or consensus statement; or the article was a case report or a case series.

We reviewed articles for all abstracts that passed screening, as well as the articles for titles that did not have abstracts associated with them, totaling 1321 English language and 409 non-English language articles. Studies were rejected if they met any of the following explicit criteria: failed abstract inclusion criteria or the article did not report any of the following clinical GI outcomes: mortality, hospitalization for a GI event, GI bleeding, GI ulcers, and any form of GI upset (including but not limited to

dyspepsia, abdominal pain, nausea, vomiting, heartburn, and pyrosis). The following report only includes results of outcomes related to PUB. We excluded studies that reported endoscopic outcomes in the absence of any relevant clinical outcomes since there are no available data to support a direct causal link between the endoscopic findings associated with NSAID use and clinical outcomes. The study population was restricted to subjects 18 years of age and older. We excluded studies in which the duration of exposure to the NSAID was less than 5 days, since such short exposures were not the focus of our clinical interest. Physicians fluent in the language of the article reviewed each non-English language article with the assistance of a study group member. We reviewed articles published in the following languages: Chinese, Danish, Dutch, Finnish, French, German, Hungarian, Italian, Japanese, Norwegian, Portuguese, Spanish, Swedish, and Russian. We did not have interpreters available for 20 studies that were written primarily in Eastern European languages. Non-English language articles did not undergo duplicate review.

Using a standardized form, elements of study quality were collected from unmasked articles that passed the article-screening phase, with disagreement resolved by consensus. Quality elements for all studies included comparability among groups (randomization for clinical trials), blinding, and treatment of withdrawals or missing data. Controlled clinical trials were scored for quality according to criteria developed by Jadad<sup>17</sup>. These criteria were developed from published clinical trial data and relied on details of blinding and randomization, and accounting for patient dropouts. The 0 to 5 quality scoring system has been shown to discriminate between clinical trials, with a score of 3 and above indicating "high quality"<sup>18</sup>. We also assessed randomized trials for concealment of allocation, but this was reported so infrequently that its discriminative value was poor.

We performed duplicate abstraction with consensus resolution for study design, study population, interventions and exposures, outcome measures, features of the analysis, and study statistics.

### FDA Review

FDA new drug application (NDA) reviews were obtained for the 5 NSAID representing 69.5% of the 1998 US prescription NSAID market: diclofenac, etodolac, ibuprofen, nabumetone, and naproxen (data on file<sup>19</sup>). Within NDA are FDA prepared summaries of the original primary data from the studies submitted by the manufacturer in support of their application. Using the same criteria applied to published studies, we examined each NDA to identify for inclusion studies that had not been published. Data extraction was performed in duplicate with consensus resolution of discrepancies. All studies were assessed for the quality of reporting using the scale developed by Jadad.

### Metaanalysis

*Stratification of studies.* Because the clinical trial and epidemiologic NSAID studies vary in their methods of capturing and reporting NSAID related GI events, we chose a priori to stratify the pooled analysis by study design and calculated estimates separately for each stratum.

*Individual study statistics.* For the randomized clinical trials and case control studies, we estimated the percentage of patients who had the outcome in the treatment and in the control groups. For cohort studies, we estimated the outcome rate per person-year observed. To assess the treatment effect, we estimated the odds ratios (OR) for randomized clinical trials (RCT) and case control studies, and the risk ratios for cohort studies.

*Data considerations.* One study used a crossover design and reported on a PUB outcome "6 weeks into the active drug period." We could not determine whether this outcome occurred in the group receiving the active drug before or after the 2 week washout period. We counted this PUB as occurring during NSAID therapy. If zero outcomes were reported for a study's control group, in order to ensure that all study statistics were defined, we applied the standard contingency table adjustment by adding a 0.5 to the treatment and control group numbers of outcomes, and a 1.0 to the numbers of patients in both the treatment and control groups.

Table 1. Search strategy.

#### Major Exploded Subject Headings

1. Non-steroidal Anti-inflammatory Agents or NSAIDS  
Or Prostaglandin Synthase Inhibitor/s And Cyclo-oxygenase Inhibitor/s  
And Gastrointestinal Diseases or Esophageal Diseases or Digestive System Diseases
2. Digestive Disease/s, Digestive Complication/s, Gastrointestinal Complication/s, Dyspepsia, Peptic or Esophageal or Stomach Ulcer/s, Gastrointestinal or Digestive Hemorrhage or Bleeding or Perforation  
And Adverse Toxic-Side Effect/s, Risk, Chemically Induced, Contraindications  
And Human Only  
Not Neoplasms, Cancer, Malignancy, Carcinoma, Adenocarcinoma/s, Case Reports, Case Studies, Case Series, Veterinary, Animal Experiment/s, Letters




Figure 1. Results of the literature search. In certain cases, there was more than one study in an article.

*Pooled estimates.* For each study design, we first excluded studies that were too clinically heterogeneous to statistically pool. For example, one cohort study was excluded from statistical pooling because it evaluated the risk of PUB in only those NSAID users with pre-existing dyspepsia<sup>20</sup>. Other studies were felt to be too clinically heterogeneous because they were not

age or sex matched, or used outcomes such as death from PUB rather than the occurrence of PUB. We then pooled statistics across all studies and within specific strata, e.g., study design, using a random effects model, which accounts for both within and between study variance, using standard formulas for the estimates and confidence intervals<sup>21,22</sup>. This is generally a

more conservative method than the fixed effect model used by prior meta-analyses, and results in wider confidence intervals. For the RCT OR, we chose Peto's method<sup>23,24</sup>. Along with the pooled estimates, we report the results of the chi-square test of heterogeneity, which tests the null hypothesis that all studies are estimating the same underlying effect. Because this test is known to have low power, nonrejection of this test does not indicate lack of heterogeneity.

*Planned subgroup analysis.* We planned to assess the effect of a variety of patient and drug variables on the association between NSAID and PUB, including patient age, presence of prior GI problems, use of concurrent medications such as corticosteroids, drug type, and drug dose, but would only do so if these variables were reported in at least 70% of the studies, in order to avoid a special form of "publication bias."

*Assessment of publication bias.* We assessed the possibility of publication bias for the RCT and cohort and case control studies. For each design separately, we evaluated a funnel plot of the log OR (RCT and case controls) and log risk ratios (cohort studies) graphically for asymmetry resulting from the non-publication of small, negative studies. Because graphical evaluation can be subjective, we also conducted an adjusted rank correlation test<sup>25</sup> and a regression asymmetry test<sup>26</sup> as formal statistical tests for publication bias. We drew these graphs and conducted these tests in the statistical package Stata<sup>27</sup>.

## RESULTS

After excluding from this analysis articles solely or predominantly about aspirin, or prophylaxis of NSAID complications with misoprostol or other agents, we identified in the published literature 55 NSAID versus placebo RCT<sup>28-81</sup>, 24 cohort studies<sup>5,20,82-103</sup>, and 57 case control studies<sup>3,4,104-158</sup>. From the FDA data, we identified an additional 37 previously unpublished NSAID versus placebo clinical trials (complete evidence tables available on request).

In general, the clinical trials were of good quality according to the classification of Jadad, with 81% of studies scoring 3 or greater. Most of the case control studies used matching on age and sex (and possibly other variables) to help enhance comparability between groups, but few studies assessed exposure status blinded to outcomes. In contrast, most of the cohort studies did not use matching or analytic comparability between NSAID users and non-NSAID users, and in 3 studies the temporal relation of NSAID exposure to the outcome was not defined.

### Summary of Effects

We estimated the risk of the more serious GI complications of PUB due to NSAID using data from RCT and cohort and case control studies (Table 2). Thirteen<sup>36,39,46,51,54,55,58,64-66,79,80</sup> published and 3 FDA NSAID versus placebo RCT reported data on PUB. Five<sup>46,54,55,64,79</sup> of the 13 published trials enrolled only patients less than 65 years, while the remainder had no upper age limit exclusion. Seven of the clinical trials studied patients with rheumatoid arthritis, 8 trials were for 4 weeks or less in duration, and 4 trials studied high doses of NSAID. There were no reports of PUB in the placebo groups of these trials, whereas the percentage of patients in the NSAID treated group was 0.2% (95% CI: 0%, 0.4%). The pooled OR is 5.36 (95% CI: 1.79, 16.1),

Table 2. Summary of results for perforations, ulcers, and bleeds.

Study Design	Number of Studies	Number of Patients <sup>‡</sup>	Odds (OR) or Risk Ratio (RR) (95% CI)
NSAID vs placebo RCT	16	4431	OR 5.36 (1.79, 16.1)
Cohort studies <sup>‡</sup>	9	758,776 patient-years	RR 2.7 (2.1, 3.5)
Case control studies <sup>‡</sup>	23	25,732	OR* 3.0 (2.5, 3.7)

<sup>†</sup> The total number of patients. <sup>‡</sup> Chi-square test of heterogeneity,  $p < 0.05$ .

\* Age and sex matched.

which is a good approximation of the relative risk since the event rate is rare.

In the cohort data, there were 13 studies<sup>20,82,83,85,87,89,91,92,94,97-99,102</sup> that reported data on PUB, representing nearly 800,000 patient-years of exposure to NSAID. Nine<sup>82,83,85,87,89,92,97,98,102</sup> of the 13 studies were judged sufficiently clinically homogeneous to synthesize, and the random effects pooled risk ratio for PUB was 2.7 (95% CI: 2.1, 3.5). Four were excluded because the study: used death from PUB rather than occurrence of PUB as the outcome<sup>91</sup>, studied patients with preexisting dyspepsia rather than an otherwise unselected population<sup>20</sup>, used a chart review to include only those PUB occurrences the investigators felt were "probably" caused by NSAID use<sup>94</sup>, and reported relative risks adjusted for many variables rather than the actual population based data<sup>99</sup>.

Among the 57 case control studies that met our criteria, 23 studies<sup>3,106-108,111-113,118,125,126,128,131,133,134,138-140,142-144,150,151,153</sup> (contributing over 25,000 patients) were judged sufficiently clinically homogeneous to pool (in that they all used age and sex matching and measured PUB as an outcome). The summary pooled OR, taken from unadjusted OR in each study, was 3.0 (95% CI: 2.5, 3.7) (Table 2).

### Subgroup Analyses

While all of the randomized clinical trials reported the drug and dose used (but rarely age or exclusion of prior GI problems), there were too few RCT reporting PUB outcomes to support subgroup analyses. Among the cohort and case control studies not one variable (age, drug, dose, etc.) was reported in more than 70% of the eligible studies. The variable reported in the greatest proportion of studies was age in the cohort studies. In the 9 cohort studies contributing data to the pooled analysis, separate analyses by age were reported for three<sup>83,97,98</sup> and 2 studies presented analysis of the relative risk of PUB by age, adjusted for multiple other variables<sup>92,102</sup>. No other variable was present in even 50% of eligible studies.

Since a recent report suggests that risk estimates may vary depending on whether studies were performed prior to 1990<sup>159</sup>, we assessed this using our data. When stratifying the analysis by whether studies were published before or after 1990, there was no statistical difference in the results

stratifying the RCT or case control studies. Only the cohort data suggest that the risk estimates may be greater in the more recent literature. The risk ratio for cohort studies published before 1990 is 2.0 (95% CI: 1.7, 2.3) with 257,652 patient-years of exposure compared to studies published in 1990 or later with a risk ratio of 3.4 (95% CI: 2.8, 4.1) with 501,124 patient-years of exposure.

#### Assessment of Publication Bias

No evidence of publication bias was apparent for either the cohort or case control studies, either graphically and or via the adjusted rank correlation test ( $p = 0.99$  and  $p = 0.92$ , respectively)<sup>25</sup>, or the regression asymmetry test ( $p = 0.41$  and  $p = 0.45$ , respectively)<sup>26</sup>. Evidence of publication bias was present among the RCT both graphically and based on the formal tests ( $p < 0.05$ ). The direction of the estimated bias suggested that small studies with NSAID related PUB outcomes were not reported.

## DISCUSSION

Valid estimates of the upper GI complications of NSAID are critical for informing treatment decisions. There is a vast literature on this topic, and from 4881 titles identified in our search, our systematic review identified 16 RCT, 9 cohort studies, and 23 case control studies. This is more than previous reviews have identified. By comparison, prior metaanalyses have identified less than 20 total studies on risk of PUB eligible for data synthesis<sup>8,11</sup>. There is empirical evidence that study design is associated with bias, with observational studies reporting exaggerated effects compared to randomized studies<sup>14</sup> and, within observational studies, those using a case control design reporting exaggerated effects compared to cohort studies<sup>160</sup>. Therefore, unlike previous metaanalyses, we refrained from pooling across study design. Particular strengths of this analysis include the use of published and unpublished RCT data to derive risk estimates to complement those obtained from observational studies, and the assessment of publication bias, particularly as it pertains to the degree to which data about subgroups are reported and the implications for the conclusions of prior studies reporting risk estimates in these subgroups.

The estimated risk ratio for PUB in our analysis varied from 5.4 in RCT to 2.7 in cohort studies to 3.0 in case control studies, all supporting a strong association. The width of the confidence interval in the RCT data make this source of risk estimate the least precise and least generalizable. The estimates from cohort data after 1990 are similar to the estimates from case control studies, and thus likely reflect the more accurate estimates from observational studies. Which estimate of risk is most relevant to practicing clinicians? We believe our estimate derived from cohort data is most relevant, for 2 reasons. First, while we expect that the estimate of risk would be least biased when derived from randomized placebo controlled trials, the populations being

studied in such trials are usually a highly select group and are not necessarily representative of the patients seen in clinical practice. Additionally, our statistical methods indicate the likely presence of publication bias with the “missing” studies being those reporting greater risk of PUB. Second, there is empiric evidence that case control studies of diagnostic tests yield exaggerated estimates of effect compared to cohort studies<sup>160</sup>, and theoretic reasons to suspect the same will be true for observational studies of risk.

With regard to subgroup analyses, our finding that patient and drug variables such as age, drug type, dose, etc., are reported in only a small fraction of available studies is cause for some concern. The pooling of subgroups in such circumstances is likely to yield exaggerated estimates of effect, as the reporting of subgroup analyses in the original studies is almost certainly not random, but rather more likely if they are “interesting” (i.e., statistically significant)<sup>161</sup>. This phenomenon of the differential reporting of subgroup analyses or secondary outcomes is a special form of “publication bias.” Prior pooled estimates that certain patient characteristics or drug and dose regimens are associated with a lesser or greater risk of PUB must be viewed with caution. There are several limitations of this analysis. First, the validity of our results is dependent upon the quality and validity of the primary data. However, most of the clinical trials were of “good” quality according to the only validated scale of quality of controlled trials. While we did identify aspects of the observational studies that are presumed to represent methodologic weaknesses, as there are at present no criteria of the methodologic quality of observational studies that has empiric validation, we did not attempt to categorize observational studies as “high” or “low” quality, or use such a classification (other than study design) in the analysis. Also, when attempting to incorporate unpublished data, we used a sample of clinically reasonable FDA data regarding the most commonly used agents, rather than reviewing all NDA reports of all NSAID.

The strengths of this analysis include our attempts to identify all relevant studies, including unpublished data and non-English language studies, and the estimation of risk stratified by variables known to produce bias (study design). Our use of a random effects model, while not a panacea for dealing with heterogeneity<sup>162</sup>, when combined with careful assessment of clinical study differences and an a priori decision to stratify based on study design, is a more robust approach than a fixed effects pooling of all studies as previously employed. The estimates derived from this analysis are based on a greater number of studies with more patients than any prior review. We believe these are the best evidence based estimates to date regarding the risk of clinically important upper GI complications associated with NSAID. These data will be helpful to clinicians when assessing the benefits and risks of NSAID therapy for their patients and in

the evaluation of new drugs or therapies intended to reduce the risk of NSAID associated upper GI complications.

## REFERENCES

1. Smalley WE, Griffin MR. The risks and costs of upper gastrointestinal disease attributable to NSAIDs. *Gastroenterol Clin North Am* 1996;25:373-96.
2. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. *Arthritis Rheum* 1993;36:447-59.
3. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. *Ann Intern Med* 1991;114:257-63.
4. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. *Ann Intern Med* 1988;109:359-63.
5. Smalley WE, Griffin MR, Fought RL, Ray WA. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. *J Gen Intern Med* 1996;11:461-9.
6. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. *Ann Intern Med* 1991;114:307-19.
7. Chalmers TC, Berrier J, Hewitt P, et al. Meta-analysis of randomized controlled trials as a method of estimating rare complications of non-steroidal anti-inflammatory drug therapy. *Aliment Pharmacol Ther* 1988;2S:9-26.
8. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal antiinflammatory drugs and upper gastrointestinal tract bleeding/perforation. *Arch Intern Med* 2000;160:2093-9.
9. Hawkey CJ. Non-steroidal anti-inflammatory drugs and peptic ulcers. *BMJ* 1990;300:278-84.
10. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. *BMJ* 1996;312:1563-6.
11. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. *Ann Intern Med* 1991;115:787-96.
12. Garcia Rodriguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. *Semin Arthritis Rheum* 1997;26 Suppl 1:16-20.
13. Stalnikowicz R, Rachmilewitz D. NSAID-induced gastroduodenal damage: Is prevention needed? *J Clin Gastroenterol* 1993; 17:238-43.
14. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I. Medical. *Stat Med* 1989;8:441-54.
15. Gregoire G, Derderian F, Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a tower of Babel bias? *J Clin Epidemiol* 1995;48:159-63.
16. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence the estimates of intervention effectiveness reported in meta-analyses? *Lancet* 2000;356:1228-31.
17. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials* 1996;17:1-12.
18. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? *Lancet* 1998;352:609-13.
19. Data on file. IMS America, Westport, CT, USA.
20. Kurata JH, Nogawa AN, Noritake D. NSAIDs increase risk of gastrointestinal bleeding in primary care patients with dyspepsia. *J Fam Pract* 1997;45:227-35.
21. Ioannidis JP, Cappelleri JC, Lau J, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. *Ann Intern Med* 1995;122:856-66.
22. Laird NM, Mosteller F. Some statistical methods for combining experimental results. *Int J Technol Assess Health Care* 1990;6:5-30.
23. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. *Prog Cardiovasc Dis* 1985;27:335-71.
24. Deeks J, Bradburn M, Localio R, Berlin J. Much ado about nothing: statistical methods for meta-analysis with rare events. Baltimore, MD. 6th Annual Cochrane Colloquium Abstracts, October 22-25, 1998. [www.cochrane.no/colloquium](http://www.cochrane.no/colloquium)
25. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50:1088-101.
26. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629-34.
27. StataCorp. Stata Statistical Software: Release 6.0. College Station, TX: Stata Corporation; 1999.
28. Amlie E, Weber H, Holme I. Treatment of acute low-back pain with piroxicam: Results of a double-blind placebo-controlled trial. *Spine* 1987;12:473-6.
29. Astrom M, Westlin N. No effect of piroxicam on achilles tendinopathy. A randomized study of 70 patients. *Acta Orthop Scand* 1992;63:631-4.
30. Balogh Z, Papazoglou SN, MacLeod M, et al. A crossover clinical trial of piroxicam, indomethacin and ibuprofen in rheumatoid arthritis. *Curr Med Res Opin* 1979;6:148-53.
31. Berkowitz SS, Bernhard G, Bilka PJ, et al. Tolmetin versus placebo for the treatment of rheumatoid arthritis: A sequential double-blind clinical trial. *Curr Ther Res* 1974;16:442-51.
32. Berry H, Bird HA, Black C, et al. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. *Ann Rheum Dis* 1992;51:238-42.
33. Berry H, Bloom B, Fernandes L, et al. Comparison of timegadine and naproxen in rheumatoid arthritis. A placebo controlled trial. *Clin Rheumatol* 1983;2:357-61.
34. Berry H, Bloom B, Hamilton EBD. A comparative study of piroxicam (Feldene), diclofenac and placebo in osteoarthritis. *Clin Trials J* 1982;19:349-58.
35. Berry H, Coquelin JP, Gordon A, et al. Antrafenine, naproxen and placebo in osteoarthritis: A comparative study. *Br J Rheumatol* 1983;22:89-94.
36. Bobrove AM, Calin A. Efficacy and tolerance of a novel precision-dose formulation of indomethacin: Double-blind trials in rheumatoid arthritis and osteoarthritis. *Curr Med Res Opin* 1983;8 Suppl 2:55-61.
37. Boeckstyns MEH, Backer M, Petersen EM, et al. Piroxicam spares buprenorphine after total joint replacement-controlled study of pain treatment in 81 patients. *Acta Orthop Scand* 1992;63:658-60.
38. Boeyinga JK, Callewaert JAM. Tiaprofenic acid (Surgam) in arthritic conditions: a randomized double-blind comparison with placebo in a multi-centre trial. *Tijdschr Ther Geneesm Onderz* 1984;9:492-6.
39. Bono RF, Finkel S, Goodman HF, et al. Oxaprozin in the treatment of patients with tendinitis and bursitis: comparison with phenylbutazone and placebo. *Semin Arthritis Rheum* 1986;15 Suppl 2:90-4.
40. Brackertz B. Comparative study of sulindac (clinoril) and ibuprofen (brufen) in osteoarthritis. *Br J Clin Pract* 1978;32:77-80.
41. Cordrey LJ. Tolmetin sodium, a new anti-arthritis drug: Double-blind and long term studies. *J Am Geriatr Soc* 1976;24:440-6.
42. Cryer B, Goldschmied M, Redfern JS, et al. Comparison of salsalate and aspirin on mucosal injury and gastroduodenal mucosal injury and gastroduodenal mucosal prostaglandins. *Gastroenterology*

- 1990;99:1616-21.
43. De Blecourt JJ, Oh BK, Bernaert AC. Tiaprofenic acid (Surgam): A double-blind crossover trial. *Tijdschr Geneesmiddelenonderz* 1982;7:1434-7.
  44. Dore R, Ballard I, Constantine G, et al. Efficacy and safety of etodolac and naproxen in patients with osteoarthritis of the knee: A double-blind, placebo-controlled study. *Clin Ther* 1995;17:656-66.
  45. Ebel DL, Rhymer AR, Stahl E, et al. Effect of clinoril (sulindac, msd), piroxicam and placebo on the hypotensive effect of propranolol in patients with mild to moderate essential hypertension. *Scand J Rheumatol* 1986;15 Suppl 62:41-9.
  46. El-Mehairy MM, Shaker A, El-Dein Bahgat N. A double blind comparison of niflumic acid with phenylbutazone, oxyphenylbutazone and placebo in the treatment of osteoarthritis. *Rheumatol Rehabil* 1974;13:198-203.
  47. Fasching U. Diflunisal vs ibuprofen in rheumatoid arthritis. Comparison of the effects of diflunisal, ibuprofen and placebo in chronic polyarthritis. In German. *Wien Klin Wochenschr* 1983;95:869-72.
  48. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. *Arthritis Rheum* 1986;29:1371-7.
  49. Hossain MA, Akbar FA, Thompson M. Floctafenine (Idarac) in the management of rheumatoid arthritis. *Rheumatol Rehabil* 1977;16:260-4.
  50. Hutson MA. A double-blind study comparing ibuprofen 1800 mg or 2400 mg daily and placebo in sports injuries. *J Int Med Res* 1986;14:142-7.
  51. Jacob GB, Hart KK, Mullane JF, et al. Placebo-controlled study of etodolac and aspirin in the treatment of rheumatoid arthritis. *Curr Ther Res* 1983;33:703-13.
  52. Kolarz G, Liem KS, Reichel H, et al. Double blind comparison of indomethacin and cloximate, a new nonsteroid antirheumatic agent. In German. *Therapiewoche* 1979;29:5898-902.
  53. Kragballe K, Herlin T. Benoxaprofen improves psoriasis. A double-blind study. *Arch Dermatol* 1983;119:548-52.
  54. Lacey PH, Dodd GD, Shannon DJ. A double blind, placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. *Eur J Rheumatol Inflamm* 1984; 7:95-104.
  55. Lanza FL, Nelson RS, Rack MF. A controlled endoscopic study comparing the toxic effects of sulindac, naproxen, aspirin, and placebo on the gastric mucosa of healthy volunteers. *J Clin Pharmacol* 1984;24:89-95.
  56. Lanza FL, Rack MF, Royer GL Jr, et al. Gastro-intestinal effects of ibuprofen, naproxen and aspirin in normal volunteers. A comparative study. *Clin Trials J* 1986;23:168-77.
  57. Lanza FL, Umbenhauer ER, Nelson RS, et al. A double-blind randomized placebo controlled gastroscopic study to compare the effects of indomethacin capsules and indomethacin suppositories on the gastric mucosa of human volunteers. *J Rheumatol* 1982;9:415-9.
  58. Lemmel E-M, Bolten W, Burgos-Vargas R, et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. *J Rheumatol* 1997;24:282-90.
  59. Lussier A, Tetreault L, Lebel E. Comparative study of gastrointestinal microbleeding caused by aspirin, fenbufen, and placebo. *Am J Med* 1983;75:80-3.
  60. Mehta S, Dasarathy S, Tandon RK, et al. A prospective randomized study of the injurious effects of aspirin and naproxen on the gastroduodenal mucosa in patients with rheumatoid arthritis. *Am J Gastroenterol* 1992;87:996-1000.
  61. Moore RA, McQuay HJ, Carroll D, et al. Single and multiple dose analgesic and kinetic studies of mefenamic acid in chronic back pain. *Clin J Pain* 1986;2:29-36.
  62. Patoia L, Clausi G, Farroni F, et al. Comparison of faecal blood loss, upper gastrointestinal mucosal integrity and symptoms after piroxicam beta-cyclodextrin, piroxicam and placebo administration. *Eur J Clin Pharmacol* 1989;36:599-604.
  63. Perez JH, Masso RM, Imizcoz BJL. Meclofenamate sodium in the treatment of post-traumatic edema. Report of a controlled double-blind study. *Arzneim Forsch Drug Res* 1983;33:663-7.
  64. Petrick TJ, Black ME. Double-blind multicenter studies with meclofenamate sodium in the treatment of rheumatoid arthritis in the United States and Canada. *Arzneim Forsch Drug Res* 1983;33:631-5.
  65. Petrick TJ, Bovenkerk WE. Multicenter studies in the United States and Canada of meclofenamate sodium in osteoarthritis of the hip and knee. Double-blind comparison with placebo and long-term experience. *Arzneim Forsch Drug Res* 1983;33:644-8.
  66. Prupas HM, Loose LD, Spindler JS, et al. Tenidap in patients with rheumatoid arthritis. A 4-week, placebo-controlled study. *Scand J Rheumatol* 1996;25:345-51.
  67. Ronen S, Rozenman Y, Zylbermann R, et al. Treatment of ocular inflammation with diclofenac sodium: double-blind trial following cataract surgery. *Ann Ophthalmol* 1985;17:577-81.
  68. Rosekrans PCM, Stoyanova M, Mak M, et al. A comparative study of sulindac (MK 231), aspirin and placebo in coxarthrosis: some problems related to the clinical evaluation of analgesic, anti-inflammatory drugs. *Pharmatherapeutica* 1976;1:52-64.
  69. Royer GL Jr, Seckman CE, Schwartz JH, et al. Effects of ibuprofen on normal subjects clinical and routine and special laboratory assessments. *Curr Ther Res* 1985;37:412-26.
  70. Sanchez JL, Yanez MG. Meclofenamate sodium, phenylbutazone, and naproxen in the treatment of degenerative joint disease. Report of a placebo-controlled double-blind clinical comparison. *Arzneim Forsch Drug Res* 1983;33:653-6.
  71. Schnitzer TJ, Ballard IM, Constantine G, et al. Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the knee. *Clin Ther* 1995;17:602-12.
  72. Stadler P, Armstrong D, Margalith D, et al. Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers. *Dig Dis Sci* 1991;36:594-600.
  73. Thillainayagam AV, Tabaqchali S, Warrington SJ, et al. Interrelationships between *Helicobacter pylori* infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease. A prospective study in healthy volunteers. *Dig Dis Sci* 1994; 39:1085-9.
  74. Thompson M, Daymond TJ, Essigman WK, et al. Short-term efficacy and tolerance of tiaprofenic acid (Surgam) in rheumatoid arthritis and osteoarthritis. Multicentre placebo-controlled trials. *Curr Med Res Opin* 1982;8:215-23.
  75. Van Der Kleijn E, Zelveler WG. Diflunisal: A placebo-controlled trial. *Tijdschr Geneesmiddelenonderz* 1982;7:1345-51.
  76. Van Der Pas HFM, Vertommen F. A double-blind study of naproxen-suppositories for post episiotomial pain compared with ASA, oxyfenbutazon and placebo. *Ars Med* 1984;39:79-81.
  77. Vargas FS, Esposito MA, Terra FM, et al. Naproxen sodium in the treatment of bronchitic infectious processes. In Spanish. *Rev Bras Med* 1983;40:144-8.
  78. Weaver A, Rubin B, Caldwell J, et al. Comparison of the efficacy and safety of oxaprozin and nabumetone in the treatment of patients with osteoarthritis of the knee. *Clin Ther* 1995;17:735-45.
  79. Weintraub M, Jacox RF, Angevine CD, et al. Piroxicam (CP 16171) in rheumatoid arthritis: a controlled clinical trial with novel assessment techniques. *J Rheumatol* 1977;4:393-404.
  80. Welch KMA, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. *Neurology* 1985;35:1304-10.
  81. Williams P, Williams P, Currie WJC, et al. A double-blind

- comparison of 'Osmosin', benoxaprofen and placebo in the treatment of osteoarthritis. *Curr Med Res Opin* 1983;8 Suppl 2:90-8.
82. Beard K, Walker AM, Perera DR, et al. Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. *Arch Intern Med* 1987;147:1621-3.
  83. Beardon PH, Brown SV, McDevitt DG. Gastrointestinal events in patients prescribed non-steroidal anti-inflammatory drugs: a controlled study using record linkage in Tayside. *Q J Med* 1989;71:497-505.
  84. Benz J, Wiedbrauck F, Hotz J. Epidemiology of antirheumatic drug-induced ulcer in comparison with peptic gastroduodenal ulcer. Five-year analysis of a hospital patient sample. In German. *Med Klin* 1993;88:463-70.
  85. Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. *Arch Intern Med* 1989;149:1019-22.
  86. Bloom BS. Risk and cost of GI side effects on non-steroidal anti-inflammatory drugs [abstract]. *Gastroenterology* 1989;96:A47.
  87. Carson JL, Strom BL, Soper KA, et al. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. *Arch Intern Med* 1987;147:85-8.
  88. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Pt 2. *Gastroenterol* 1989;96 Suppl:647-55.
  89. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models [see comments]. *Am J Med* 1991;91:213-22.
  90. Griffin MR, Smalley WE. Drugs and ulcers: clues about mucosal protection from epidemiologic studies. *J Clin Gastroenterol* 1995;21 Suppl 1:S113-9.
  91. Guess HA, West R, Strand LM, et al. Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. *J Clin Epidemiol* 1988;41:35-45.
  92. Hallas J, Lauritsen J, Villadsen HD, et al. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. *Scand J Gastroenterol* 1995;30:438-44.
  93. Janssen M, Dijkmans BAC, Van der Sluys FA, et al. Upper gastrointestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases. *Br J Rheumatol* 1992;31:747-52.
  94. Jick H, Feld AD, Perera DR. Certain nonsteroidal antiinflammatory drugs and hospitalization for upper gastrointestinal bleeding. *Pharmacotherapy* 1985;5:280-4.
  95. Jones RH, Tait CL. Gastrointestinal side-effects of NSAIDs in the community. *Br J Clin Pract* 1995;49:67-70.
  96. Leufkens HG, Ruter EM, Ameling CB, et al. Linkage of pharmacy data on heavy users of nonsteroidal anti-inflammatory drugs to information from general practitioners. *J Pharmacoepidemiol* 1991;2:67-77.
  97. MacDonald TM, Morant SV, Robinson G, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: Cohort study. *BMJ* 1997; 315:1333-7.
  98. McMahon AD, Evans JM, White G, et al. A cohort study (with re-sampled comparator groups) to measure the association between new NSAID prescribing and upper gastrointestinal hemorrhage and perforation. *J Clin Epidemiol* 1997;50:351-6.
  99. Rodriguez LAG, Walker AM, Perez Gutthann S. Nonsteroidal anti-inflammatory drugs and gastrointestinal hospitalizations in Saskatchewan: a cohort study. *Epidemiol* 1992;3:337-42.
  100. Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. *Arch Intern Med* 1993;153:1665-70.
  101. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. *Arch Intern Med* 1996;156:1530-6.
  102. Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. *Am J Epidemiol* 1995;141:539-45.
  103. Talley NJ, Evans JM, Fleming KC, et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. *Dig Dis Sci* 1995;40:1345-50.
  104. Abenhaim L, Moride Y. The effect of baseline susceptibility on the relative gastrototoxicity of individual NSAIDs in the elderly: A study with the Quebec database [abstract]. *Postmarketing Surveillance* 1993;7:176.
  105. Alexander AM, Veitch GBA, Wood JB. Anti-rheumatic and analgesic drug usage and acute gastro-intestinal bleeding in elderly patients. *J Clin Hosp Pharm* 1985;10:89-93.
  106. Bartle WR, Gupta AK, Lazor J. Nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding. A case-control study. *Arch Intern Med* 1986;146:2365-7.
  107. Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. *Aliment Pharmacol Therap* 1997;11:283-91.
  108. Chan TY, Critchley JA, Lau JT, et al. The relationship between upper gastrointestinal hemorrhage and drug use: a case control study. *Int J Clin Pharmacol Ther* 1996;34:304-8.
  109. Clinch D, Banerjee AK, Levy DW, et al. Non-steroidal anti-inflammatory drugs and peptic ulceration. *J R Coll Physicians Lond* 1987;21:183-7.
  110. Coggon D, Langman MJ, Spiegelhalter D. Aspirin, paracetamol, and haematemesis and melaena. *Gut* 1982;23:340-4.
  111. Collier DS, Pain JA. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. *Gut* 1985;26:359-63.
  112. de Boer SY, van Berge Henegouwen GP, Kluitman EM. Non-steroidal anti-inflammatory drugs and hemorrhage from stomach and duodenal ulcers. In Dutch. *Ned Tijdschr Geneesk* 1988;132:160-3.
  113. Duggan JM, Dobson AJ, Johnson H, et al. Peptic ulcer and non-steroidal anti-inflammatory agents. *Gut* 1986;27:929-33.
  114. Faulkner G, Prichard P, Somerville K, et al. Aspirin and bleeding peptic ulcers in the elderly. *BMJ* 1988;297:1311-3.
  115. Gilles M, Skyring A. Gastric ulcer, duodenal ulcer and gastric carcinoma: A case-control study of certain social and environmental factors. *Med J Aust* 1968;2:1132-6.
  116. Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. *Epidemiol* 1997;8:18-24.
  117. Hawkey GM, Everitt S, Pearson GM, et al. Non-steroidal anti-inflammatory drugs and *Helicobacter pylori* as independent risk factors for peptic ulcer bleeding [abstract]. *Gastroenterology* 1997;114 Suppl:A114.
  118. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. *Gastroenterol* 1993;105:1078-88.
  119. Henry DA, Johnston A, Dobson A, et al. Fatal peptic ulcer complications and the use of non-steroidal anti-inflammatory drugs, aspirin, and corticosteroids. *BMJ* 1987;295:1227-9.
  120. Hirschowitz BI, Lansas A. NSAID association with gastrointestinal bleeding and peptic ulcer. *Agents Actions Suppl* 1991;35:93-101.
  121. Hochain P, Berkelmans I, Czernichow P, et al. Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. *Eur J Gastroenterol Hepatol* 1995;7:419-26.
  122. Holt S, Rigoglioso V, Sidhu M, et al. Nonsteroidal antiinflammatory drugs and lower gastrointestinal bleeding. *Dig Dis Sci*



- 1993;38:1619-23.
123. Holvoet J, Terriere L, Van Hee W, et al. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study. *Gut* 1991;32:730-4.
  124. Imhof M, Ohmann C, Hartwig A, et al. Which peptic ulcers bleed? Results of a case-control study. *Dusuk studygroup. Scand J Gastroenterol* 1997;32:131-8.
  125. Jick SS, Perera DR, Walker AM, et al. Non-steroidal anti-inflammatory drugs and hospital admission for perforated peptic ulcer. *Lancet* 1987;2:380-2.
  126. Kaufman DW, Kelly JP, Sheehan JE, et al. Nonsteroidal anti-inflammatory drug use in relation to major upper gastrointestinal bleeding. *Clin Pharmacol Ther* 1993;53:485-94.
  127. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product [see comments]. *Lancet* 1996;348:1413-6.
  128. Keating J, Chandran H. Antiinflammatory drugs and emergency surgery for peptic ulcers in the Waikato. *N Z Med J* 1992;105:127-9.
  129. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. *Gastroenterol* 1992;103:862-9.
  130. Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. *Gastroenterol* 1997;112:683-9.
  131. Langman MJ. The role of analgesic antirheumatic drugs in precipitating acute upper gastrointestinal bleeding. *Proc R Soc Med* 1977;70 Suppl 7:16-7.
  132. Langman MJS, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. *BMJ* 1985;290:347-9.
  133. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. *Lancet* 1994;343:1075-8.
  134. Laporte JR, Carne X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. *Catalan Countries Study on Upper Gastrointestinal Bleeding* [see comments]. *Lancet* 1991;337:85-9.
  135. Laszlo A, Kelly JP, Kaufman DW, et al. The etiology of upper gastrointestinal bleeding in Hungary: The role of non-steroidal anti-inflammatory drugs, alcohol, coffee and smoking (based on the 'Boston-Stockholm-Budapest' international, multicentric case-control study). *Orvosi Hetilap* 1995;136:2771-7.
  136. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. *N Engl J Med* 1974;290:1158-62.
  137. Levy M, Miller DR, Kaufman DW, et al. Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics. *Arch Intern Med* 1988;148:281-5.
  138. Martio J. The influence of antirheumatic drugs on the occurrence of peptic ulcers. A controlled study of patients with chronic rheumatic diseases. *Scand J Rheumatol* 1980;9:55-9.
  139. Matikainen M, Kangas E. Is there a relationship between the use of analgesics and non-steroidal anti-inflammatory drugs and acute upper gastrointestinal bleeding? A Finnish case-control prospective study. *Scand J Gastroenterol* 1996;31:912-6.
  140. McIntosh JH, Fung CS, Berry G, et al. Smoking, nonsteroidal anti-inflammatory drugs, and acetaminophen in gastric ulcer. A study of associations and of the effects of previous diagnosis on exposure patterns [see comments]. *Am J Epidemiol* 1988;128:761-70.
  141. McIntosh JM, Byth K, Piper DW. Environmental factors in the etiology of chronic gastric ulcer: A case control-study of exposure variables before the first symptoms. *Gut* 1985;26:789-98.
  142. Neil GA, Johlin FC, Garner LM, et al. Risk factors associated with upper gastrointestinal bleeding a case control study. II [abstract]. *Gastroenterology* 1992;102:A133.
  143. Nobili A, Mosconi P, Franzosi MG, et al. Non-steroidal anti-inflammatory drugs and upper gastrointestinal bleeding, a post-marketing surveillance case-control study. *Pharmacoepidemiol Drug Safety* 1992;1:65-72.
  144. Philp I, Upadhyay R, Russell RI. The elderly are especially at-risk from upper gastrointestinal haemorrhage associated with non-steroidal anti-inflammatory drugs. *J Clin Exp Gerontol* 1987;9:179-88.
  145. Piper DW, McIntosh JH, Ariotti DE, et al. Analgesic ingestion and chronic peptic ulcer. *Gastroenterol* 1981;80:427-32.
  146. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. *Ann Intern Med* 1991;114:735-40.
  147. Rodriguez LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. *Lancet* 1994;343:769-772.
  148. Rodriguez LAG, Cattanzuzi C, Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with Ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other anti-hypertensive drugs. *Arch Intern Med* 1998;158:33-9.
  149. Ryan P, Shearman DJ, McMichael AJ. Risk factors for ulcerative reflux oesophagitis: A case-control study. *J Gastroenterol Hepatol* 1995;10:306-12.
  150. Savage RL, Moller PW, Ballantyne CL, et al. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy [see comments]. *Arthritis Rheum* 1993;36:84-90.
  151. Smedley FH, Taube M, Leach R, et al. Non-steroidal anti-inflammatory drug ingestion: retrospective study of 272 bleeding or perforated peptic ulcers. *Postgrad Med J* 1989;65:892-5.
  152. Somerville KW, Faulkner G, Langman MJS. Risk factors for non-steroidal anti-inflammatory drug-associated upper gastrointestinal bleeding. *Eur J Gastroenterol Hepatol* 1992;4:645-9.
  153. Somerville K, Faulkner G, Langman M. Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. *Lancet* 1986;1:462-4.
  154. Traversa G, Walker AM, Menitti I. Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs. *Epidemiol* 1995;6:49-54.
  155. Valman HB, Parry DJ, Coghill NF. Lesions associated with gastroduodenal haemorrhage, in relation to aspirin intake. *BMJ* 1968;4:661-3.
  156. Voskuyl AE, Van de Laar MA, Moens HJ, et al. Extra-articular manifestations of rheumatoid arthritis: risk factors for serious gastrointestinal events. *Ann Rheum Dis* 1993;52:771-5.
  157. Weaver GA, Harper RL, Storey JA, et al. Nonsteroidal antiinflammatory drugs are associated with gastric outlet obstruction. *J Clin Gastroenterol* 1995;20:196-8.
  158. Wilcox CM, Alexander LN, Cotsonis GA, et al. Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. *Dig Dis Sci* 1997;42:990-7.
  159. Hernandez-Diaz S, Garcia Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. *Arch Intern Med* 2000;160:2093-9.
  160. Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. *JAMA* 1999;282:1061-6.
  161. Williamson P, Hutton J, Hahn S, et al. Bias in meta-analysis due to within study selective reporting. VII Cochrane Colloquium. *The Best Evidence for Health Care: The Role of the Cochrane Collaboration*. Rome, Italy, October 6-9, 1999.
  162. Poole C, Greenland S. Random-effects meta-analyses are not always conservative. *Am J Epidemiol* 1999;150:469-75.